DICICCO WENDY F
DICICCO WENDY F's purchase track record
DICICCO WENDY F has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/20/2024 | EYPT | $20K | +19.3% | -15.3% | +9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Transaction History
| EYPT | ▲ Buy | Open Market | 2,567 | $20K | 8/20/2024 | View on chart |
| AKTX | ▲ Buy | Grant | 158,473,915 | $0 | 5/1/2024 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 3,000 | $0 | 2/9/2023 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 2,500 | $0 | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Yahoo article highlights EYPT as a potential portfolio addition
A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.
Yahoo article highlights EYPT as a potential portfolio addition. A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.